MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522058-38-00

Enrollment

200

Registered

2026-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive rare cancer, HER2 positive non-small cell lung cancer, HER-positive non rare tumor type, HER2 positive bladder cancer

Brief summary

Objective response rate (ORR-18W) as per RECIST V1.1. as per investigator assessment, per cohort

Detailed description

Duration of response (DoR) Progression free rate at 18W (PFR-18W) Progression-Free survival (PFS) Overall survival (OS) Safety as per NCI-CTCAE V6.0, EQ-5D-5L questionnaire, Length of hospital stays (LOS) including acute care hospitalizations (resuscitation unit, intensive care, etc.), home care hospitalizations and follow-up and rehabilitation care

Interventions

DRUGEnhertu 100 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR-18W) as per RECIST V1.1. as per investigator assessment, per cohort	—

Secondary

Measure	Time frame
Duration of response (DoR) Progression free rate at 18W (PFR-18W) Progression-Free survival (PFS) Overall survival (OS) Safety as per NCI-CTCAE V6.0, EQ-5D-5L questionnaire, Length of hospital stays (LOS) including acute care hospitalizations (resuscitation unit, intensive care, etc.), home care hospitalizations and follow-up and rehabilitation care	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 10, 2026